Kornimate/medical-research-clean huggingface dataset:
south danish diabetes study: evaluation of the antidiabetic treatment of type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the primary objective of this study is: * to investigate whether insulin aspart with meals is better than a standard treatment with insulin nph at bedtime, evaluated by hba1c. the secondary objectives of this study are: * to study if a combination treatment with metformin and/or rosiglitazone and insulin aspart with meals is better than a standard treatment with insulin nph combined with one or more of the above oral antidiabetic drugs. according to the hypothesis, special focus will be given to the treatment group with insulin aspart combined with metformin and rosiglitazone. the treatment effect will be evaluated by hba1c. * to examine the effects of the treatments on glucose metabolism and beta cell function, evaluated by diurnal blood glucose, fasting plasma glucose, insulin, c-peptide, and lactate. * to examine the effects of the treatments on cardiovascular risk factors evaluated by serum lipid profiles, serum free fatty acids, urine albumin/creatinine ratio, and electrocardiogram (ecg). * to quantify and describe the patients' subjective experiences of the two different insulin treatments (quality of life assessment) * to examine patients with type 2 diabetes for the presence of variability in a series of genes, which are known to or are assumed to: * affect the long term outcome; * determine the responsiveness to treatment with diet, exercise and drugs targeting the known risk markers for late diabetic complications; and * after intervention, to analyse the complex interrelationships between genotypes and clinical endpoints and the responsiveness to actual treatment modalities.


Eligibility criteria:
inclusion criteria: * ages between 30 and 70 years * fasting c-peptide \>300 pmol/l * body mass index (bmi) \> 25 kg/m2 * diabetes for more than 2 years * pharmacological antidiabetic treatment for more than 3 months * 7.0%\<hba1c\<12.0% at randomisation * patient willing to sign informed consent * fertile women: negative pregnancy test and use of oral or intra-uterine contraception or depot gestagen. exclusion criteria: * s-creatinine \> 120 μmol/l * history of intolerance to metformin or glitazones * s-alat/s-asat \> 2.5 x upper normal limit * total cholesterol \> 10 mmol/l * total triglyceride \> 8 mmol/l * hemoglobin (hb) \< normal range * treatment with glitazone preceding 30 days new york heart association (nyha) functional class iii or iv * night work * present or planned pregnancy * poor vision impeding insulin administration * unawareness of hypoglycaemia (complete or partly) * mental illness or alcohol abuse * clinically relevant major organ or systemic illness * uncontrolled hypertension \>180/110 mmhg, systolic or diastolic * steroid treatment * severe lung disease * a history of malign disease * an expectation that the patient will not be collaborative or will not be able to understand the character of this trial

Keywords: type 2 diabetes insulin aspart insulin nph metformin rosiglitazone
role of ldh as a predictor of treatment outcomes in hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma represents the commonest primary cancer of the liver.serum lactate dehydrogenase is an indirect marker of tumor hypoxia,angioneogenesis and worse prognosis.

hepatocellular carcinoma (hcc) represents the commonest primary cancer of the liver. incidence is increasing and hcc has risen to become the 5th commonest malignancy worldwide and the third leading cause of cancer related death, exceeded only by cancers of the lung and stomach. hcc prevalence is higher in sub-saharan africa, central and southeast asia.serum lactate dehydrogenase (ldh) levels is an indirect marker of tumor hypoxia, angioneogenesis and worse prognosis. lactic dehydrogenase (ldh), which is a glycolytic enzyme, composed of four polypeptide chains, each one encoded by separate gene (m and h), exists in various types of human tissue and neoplasms. ldh is a key enzyme in the conversion pyruvate to lactate under anaerobic conditions .five isoforms of ldh have been identified as a result of the five different combinations of polypeptide subunits. hypoxia represents a clinical biological mechanism for treatment resistance in cancer cells via the formation of new blood vessels. furthermore, a growing body of evidence indicates that hypoxia might actually promote cancer development.

Eligibility criteria:
inclusion criteria: * patients with hepatocellular carcinoma diagnosed by biopsy or imaging criteria and alpha feto protein. * signed informed consent before registration in study * eastern cooperative oncology groups performance status between 0 and 2. exclusion criteria: * cachexia or poor condition * pregnant or human chorionic gonadotropin positive * patient with another liver tumor * any previous treatment
multi-centre study to assess the long-term performance of the deltamotion cup system in primary hip replacement surgery

Conditions: Rheumatoid Arthritis; Osteoarthritis; Post-traumatic Arthritis; Avascular Necrosis; Traumatic Femoral Fractures; Congenital Hip Dysplasia

Summary: the purpose of this study is to monitor the performance of the deltamotion cup system in the treatment of patients with hip joint disease requiring a total hip replacement.patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments.


Eligibility criteria:
inclusion criteria i) male or female subjects, aged between 18 and 70 years inclusive. ii) subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained. iii) subjects who, in the opinion of the investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups. iv) subjects suitable for a cementless total hip replacement using the deltamotion cup system, in accordance with all applicable instructions for use exclusion criteria i) subjects who, in the opinion of the investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation. ii) women who are pregnant. iii) subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes. iv) subjects who have participated in a clinical investigation with an investigational product in the last 12 months. v) subjects who are currently involved in any injury litigation claims.

Keywords: arthroplasty replacement hip cementless ceramic on ceramic
effects of urinary kallidinogenase in acute ischemic stroke patients with abnormal glucose metabolism

Conditions: Acute Ischemic Stroke; Abnormal Glucose Metabolism

Summary: urinary kallidinogenase may assist recovery acute ischemic stroke. this study evaluated the impact of urinary kallidinogenase on nihss score, modified rankin scale (mrs) score and fasting glucose levels in patients with ais combined with diabetes mellitus and impaired fasting glucose.

patients with ais and abnormal glucose metabolism were enrolled in this prospective cohort study and divided into two groups. the huk group were treated with urinary kallidinogenase and standard treatment, the control group received standard treatment. nihss scores, mrs scores and fasting blood glucose were evaluated and compared.

Eligibility criteria:
inclusion criteria: * aged 18-75 years (male or female) * patients were admitted to hospital within 72h of stroke onset * diagnosis of acute ischemic stroke according to the criteria stated in the guidelines for the diagnosis and treatment of acute ischemic stroke in china (2010), and patients were confirmed as acute ischemic cerebrovascular disease by head computed tomography (ct) or magnetic resonance imaging (mri) and diffusion weighted imaging (dwi) * nihss score ranged from 3-21 points * patients were previously diagnosed with type 2 diabetes, in which they were in line with the 2006 who diagnostic criteria for diabetes, or they had fasting blood glucose of 6.1-6.9mmol/l and glycosylated hemoglobin (hba1c) of\>6.1% * patients could cooperate with the test and evaluation of relevant indicators in the trial. exclusion criteria: * pregnant or lactating women * patients with severe heart, liver and kidney dysfunction * patients with a history of cerebrovascular disease and who still suffered from serious neurological dysfunction that had an influence on the trial * patients with physical disabilities, joint deformities or muscle lesions * patients were confirmed with intracranial hemorrhage by ct * patients were allergic to the study drug * patients suffering from severe systemic infection * patients who had participated in other clinical trials within 1 month * for any reason, the researchers believed that the subject was unlikely to complete the study (such as cerebral infarction caused by cerebral embolism, intracranial arteritis, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil) and moyamoya disease; patients undergoing thrombolysis or thrombectomy after admission; patients and their families were unable to cooperate with follow-up.)
the use of warmed saline in vaso-occlusive episodes

Conditions: Sickle Cell Disease; Sickle Cell Crisis

Summary: the purpose of this study is to determine if warming the intravenous (iv) fluid given to patients with sickle cell disease who are experiencing painful episodes known as vaso-occlusive episodes; will decrease rates of hospital admission, decrease amounts of iv pain medications given, improve pain and improve global comfort.

vaso-occlusive crisis (voc) is a common painful complication of sickle cell disease and is the primary reason that these patients seek medical care in the acute care setting. this complication arises when blood vessels are obstructed by sickled red blood cells resulting in ischemic injury. the standard management of these painful episodes comprises the administration of opioid analgesics, the infusion of intravenous (iv) fluids at room temperature and rest. these episodes often last five to seven days and many patients require inpatient management for continued administration of intravenous analgesics. the public health impact of the disease is large as admissions frequently result in school or work absences and can be financially and emotionally taxing. it is well established that exposure to cold precipitates voc. for this reason, management of the pain of voc in some centers includes the use of warming blankets as an adjunct for pain relief. it is conceptually appealing to conjecture that warm fluids might have similar salutary effects on voc. this conjecture is bolstered by the physiologic effect of temperature on vascular tone. specifically, it is well established that cold temperatures cause vasoconstriction whereas warm temperatures cause vasodilation. we expect that warmed fluids will similarly induce vasodilation, improving blood flow to vaso-occluded ischemic areas.

Eligibility criteria:
inclusion criteria: * vaso-occlusive episode defined as a pain rating of 3 or above on the wong-baker faces score in a child with an established diagnosis of sickle cell disease (ss, sc or s β thalassemia) * 4-21 years of age exclusion criteria: * fever (temperature greater than 38 degrees celsius) * inability to complete faces pain scale * evidence of acute chest syndrome clinically or radiographically * deemed by attending physician to be so ill as to need immediate hospital admission.
silk-like fabric for the prevention of pressure sores in a long term care setting

Conditions: Pressure Ulcers

Summary: the primary purpose of this research study is to evaluate if dermatherapy® bedding will significantly reduce pressure ulcer incidence by decreasing maceration, friction, and shearing among residents of nursing homes.

additional objectives of this research study are: * to evaluate healing of pressure ulcers already present or pressure ulcers that develop during the study. * to evaluate the effectiveness of dermatherapy® bedding and alternative diapers to reduce the potential for bacterial contamination associated with patients' bed linens, underpads, gowns and pajamas, and thereby help reduce the incidence of facility-acquired infections. study nurses will assess the skin of the subjects once or twice a week for the presence of pressure ulcers and measure the size of the pressure ulcers if they are present. study nurses will also obtain bacterial culture swabs of the bedding weekly for the first eight weeks of the study from five participants in each group.

Eligibility criteria:
inclusion criteria: * residents admitted for long term care. * residents admitted for hospice care with an expected length of stay greater than one week. * residents with an expected length of stay equal to or greater than 90 days.

Keywords: pressure ulcers stage 1 stage 2 stage 3 stage 4 wounds sores infection bioburden bacterial contamination bed linen sheets underpad skin assessment microclimate shear friction moisture fabrics long term care nursing home decubitus ulcer bed ridden anti-microbial
anticonvulsant mood stabilizers, antipsychotic drugs and the insulin resistance syndrome

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder

Summary: the objective of this study is to determine the effect of various mood stabilizers (ms) on the insulin resistance syndrome (irs; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (apds). patients will be switched from their current antipsychotic medication to aripiprazole (abilify) or ziprasidone (geodon) (unless clinically contraindicated) for comparison with metabolic levels during treatment with the former medication. the metabolic syndrome is an empirical concept based on extensive evidence that a constellation of 5 metabolic abnormalities, e.g. increased cholesterol, hypertension, low hdl, taken together, predict marked increases in the risk of cvd, stroke and some types of cancer.


Eligibility criteria:
inclusion criteria to be eligible, patients must : * be male or female, age 18-65 * be diagnosed with schizophrenia, schizoaffective disorder or bipolar disorder with psychotic features according to dsm-iv criteria * be currently receiving antipsychotic drugs (clozapine, haloperidol, olanzapine, quetiapine, or risperidone) (apds) alone, mood stabilizer(s) (ms) alone, or a combination of the two * have a history of compliance with the above medication * have presumptive irs as indicated by a tg/hdl ratio \> 3.5 on current antipsychotic medication * be medicaid eligible or maintain insurance covering requested lab procedures * be able to provide written informed consent exclusion criteria a patient will be considered ineligible if he/she: * has a diagnosis other than schizophrenia, schizoaffective disorder or bipolar disorder with psychotic features according to dsm-iv criteria. * has a history of noncompliance with prescribed psychiatric medications * has a tg/hdl ratio \< 3.5 on current medication * is uninsured or is unable to self-pay potential costs of required lab procedures not covered by insurance. * is unable to provide written informed consent. * (females only) is pregnant, lactating or plans to become pregnant during study participation exclusion criteria: -

Keywords: schizophrenia schizoaffective disorder bipolar disorder metabolic syndrome
non-inferiority trial of oral tranexamic acid vs. intravenous tranexamic acid in joint replacement surgery

Conditions: Osteoarthritis; Blood Loss, Surgical; Blood Loss, Postoperative

Summary: the purpose of this research is to determine if the oral form of a medication (tranexamic acid) to reduce bleeding can be used in place of an intravenous (iv) form, to learn the best way to give tranexamic acid: either a pill by mouth, or a solution by vein.

the purpose of this research is to determine if the oral form of a medication (tranexamic acid) to reduce bleeding can be used in place of an intravenous (iv) form.to learn the best way to give tranexamic acid: either a pill by mouth, or a solution by vein. tranexamic acid is a medicine that reduces blood loss and reduces the need for blood transfusions in surgery. this drug is not experimental and has been used widely to treat patients in many settings, including orthopedic procedures, to reduce bleeding. this medication is now part of the standard of care at many centers in the u.s. and around the world. orthopedic procedures have used iv tranexamic acid more often, but there are reasons to believe that the oral form may be at least equivalent and perhaps better at lower cost to the health care system. no other study has yet performed a systematic comparison to answer the question.

Eligibility criteria:
inclusion criteria: * to be included into this study, you must be undergoing hip or bilateral knee replacement surgery. * you must be healthy enough to undergo joint replacement surgery. * you must be able to understand and sign an informed consent. * you must be at least 18 years of age. exclusion criteria: * you cannot be under 18 years of age. * you cannot be undergoing revision hip or revision bilateral knee replacement surgery. * you cannot be part of this study if you are allergic to the medication * you cannot participate if you are on hemodialysis, * you cannot participate if you have active coronary artery disease and if you have various vascular stents in place. * you will also be excluded if you have ever had a blood clot (deep vein thrombosis (dvt), pulmonary embolism (pe)). * you will also be excluded if you have ever had a cerebral or subarachnoid hemorrhage (brain bleeding), or stroke (cerebral vascular accident or transient ischemic attack). * if you are on estrogen-containing medication (hormone replacement therapy or oral contraceptive) within 7 days of surgery, you cannot take part in this study.

Keywords: tranexamic acid blood loss total hip replacement bilateral knee replacement
explore the relationship between the percentage of colonoscopy withdrawal overspeed and the adr

Conditions: Colonoscopy; Artificial Intelligence; Gastrointestinal Disease; Deep Learning

Summary: in this study, the investigators used the optical flow method to measure the colonoscopy withdrawal speed, and doctors were selected from multiple hospitals to collect prospective colonoscopy screening videos, and the percentage of colonoscopy withdrawal overspeed was calculated to explore the relationship between it based on optical flow method and the adenoma detection rate.

study showed that adequate withdrawal time is an important prerequisite for full mucosal inspection. in a large population-based analysis, a 1-min increase in withdrawal time led to a 3.6% increase in the adr. protocols or expert consensus recommend a standard withdrawal time of 6 min or longer. however, findings of studies showed that a number of colonoscopies had a withdrawal time less than 6 min, which greatly reduces the adr. investigator's preliminary experiments have shown that deep learning can monitor the colonoscopy withdrawal time in real-time and improve the adenoma detection rate. based on the above rich foundation of preliminary work and the massive demand for improving the colonoscopy withdrawal assessment system. the investigators improved endoangel to use optical flow method to monitor the colonoscopy withdrawal speed. the performance of the endoangel system was verified in colonoscopy videos. the investigators then aimed to evaluate whether the endoangel system could improve polyp detection rate after restricting the colonoscopy withdrawal speed.

Eligibility criteria:
inclusion criteria: 1. male or female ≥18 years old; 2. able to read, understand and sign an informed consent; 3. the investigator believes that the subjects can understand the process of the clinical study, are willing and able to complete all study procedures and follow-up visits, and cooperate with the study procedures; 4. patients requiring screening colonoscopy. exclusion criteria: 1. have drug or alcohol abuse or mental disorder in the last 5 years; 2. pregnant or lactating women; 3. patients with known multiple polyp syndrome; 4. patients with known inflammatory bowel disease; 5. known intestinal stenosis or space-occupying tumor; 6. known colon obstruction or perforation; 7. patients with a history of colorectal surgery; 8. patients with a previous history of allergy to pre-used spasmolysis; 9. unable to perform biopsy and polyp removal due to coagulation disorders or oral anticoagulants; 10. high-risk diseases or other special conditions that the investigator considers the subject unsuitable for participation in the clinical trial.
intra-bone cord blood transplantation in patients with haematological malignancies

Conditions: High Risk Haematological Malignancies; Advanced Haematological Malignancies

Summary: cord blood (cb) from an unrelated donor is increasingly used an alternative source of hematopoietic stem cells for adults with hematologic malignancies who lack an hla-matched donor. however, the utilization of single-unit cb for transplantation of adult patients has been impeded by the low number of nucleated cells available from individual cb units. direct intrabone cb injection (ibcbi) has been recently investigated as a solution to cell dose problem in adults, with the aims of minimizing non-specific loss of progenitors. we set up a phase i-ii study to assess the safety and efficacy of cb transplantation by ibcbi in adult patients with advanced or high-risk hematological malignancies


Eligibility criteria:
inclusion criteria: * advanced or high risk haematological malignancies * age 18-65 years * no suitable unrelated hla-matched donors identified in a clinically useful time-frame * informed consent exclusion criteria: * active infectious disease at inclusion * hiv- positivity or active hepatitis infection * impaired liver function (bilirubin \> upper normal limit; transaminases \> 3.0 x upper normal limit) at inclusion * impaired renal function (creatinine-clearance \ 1.5 x upper normal limit) at inclusion * psychiatric diseases or conditions that might impair the ability to give informed consent

Keywords: haematological malignancies allogeneic cord blood transplantation intrabone
blood pressure control and compliance to treatment in hypertensive patients with metabolic syndrome: a study based on home blood pressure telemonitoring and assessment of psychological determinants

Conditions: Arterial Hypertension; Metabolic Syndrome

Summary: the purpose of this study is to assess whether, in patients at high cardiovascular risk (hypertension with metabolic syndrome), long-term (1-year) blood pressure control is most effective when based on home blood pressure telemonitoring and on the feedback to the patient by the doctor between visits, or when based only on blood pressure determination during quarterly office visits.


Eligibility criteria:
inclusion criteria: * treated or untreated uncontrolled essential arterial hypertension (office systolic blood pressure \>140 or diastolic \>90 mmhg + day-time systolic blood pressure \>135 or day-time diastolic blood pressure \>85 mmhg) * metabolic syndrome (atp iii criteria) exclusion criteria: * secondary arterial hypertension * severe liver or kidney disease * immunological disease * cardiac arrhythmias

Keywords: arterial hypertension metabolic syndrome home blood pressure ambulatory blood pressure office blood pressure telemedicine